Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Purple Biotech (PPBT) Equity Average (2016 - 2025)

Purple Biotech has reported Equity Average over the past 6 years, most recently at $49.6 million for Q4 2022.

  • Quarterly Equity Average fell 26.23% to $49.6 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $49.6 million through Dec 2022, down 26.23% year-over-year, with the annual reading at $56.1 million for FY2022, 22.54% down from the prior year.
  • Equity Average was $49.6 million for Q4 2022 at Purple Biotech, down from $53.9 million in the prior quarter.
  • Over five years, Equity Average peaked at $77.4 million in Q1 2021 and troughed at $9.7 million in Q2 2018.
  • The 5-year median for Equity Average is $55.4 million (2022), against an average of $46.8 million.
  • Year-over-year, Equity Average soared 509.49% in 2020 and then fell 26.23% in 2022.
  • A 5-year view of Equity Average shows it stood at $10.8 million in 2018, then increased by 2.91% to $11.1 million in 2019, then soared by 509.49% to $67.9 million in 2020, then dropped by 1.04% to $67.2 million in 2021, then decreased by 26.23% to $49.6 million in 2022.
  • Per Business Quant, the three most recent readings for PPBT's Equity Average are $49.6 million (Q4 2022), $53.9 million (Q3 2022), and $57.0 million (Q2 2022).